Evaluation of the mutagenic effect of the new fungicide trimorphamide.
The new Czechoslovak fungicide trimorphamide was tested for its mutagenic activity. To evaluate the potential mutagenic effects on Drosophila, trimorphamide at 0.5, 1.0, 5.0, 10.0% was administered into the cultivation medium, and the sex-linked recessive lethal mutation detection test and the chromosome nondisjunction test were used. After administration of trimorphamide to mice at 60, 150 and 300 mg . kg-1 b.w. perorally, and 30, 70 and 150 mg . kg-1 b.w. intraperitoneally in single and repeated (5X) doses, a cytogenetic analysis of chromosomal aberrations in bone-marrow cells was performed. The cytogenetic analysis of human peripheral lymphocytes for chromosomal aberrations in vitro was performed 24 h after trimorphamide had been applied into the culture in concentrations 19.1 X 10(-3), 19.1 X 10(-4) and 19.1 X 10(-5) M. Under our testing conditions the trimorphamide concentrations used did not show any mutagenic effect upon Drosophila, compared with the controls. Also, under the conditions of the cytogenetic analysis, no significant increase in the frequency of chromosomal abnormalities in mouse bone marrow or in human peripheral lymphocyte was observed compared with the group of controls.
D000818:Animals; D001853:Bone Marrow / Q000648:ultrastructure; D002869:Chromosome Aberrations; D004331:Drosophila melanogaster / Q000187:drug effects; D005260:Female; D005659:Fungicides, Industrial / Q000494:pharmacology*; D006801:Humans; D008214:Lymphocytes / Q000648:ultrastructure; D008297:Male; D051379:Mice; D009025:Morpholines / Q000494:pharmacology*; D009152:Mutagenicity Tests; D009153:Mutagens
D005659:Fungicides, Industrial; D009025:Morpholines; D009153:Mutagens; C024814:trimorfamid